(Q45449583)

14 December 2017

Duration of virus shedding after trivalent intranasal live attenuated influenza vaccination in adults (English)

1 reference

14 December 2017

1 reference

8

Kathryn M Edwards

1 reference

14 December 2017

Thomas R Talbot

1

1 reference

14 December 2017

Deidre D Crocker

2

1 reference

14 December 2017

Jody Peters

3

1 reference

14 December 2017

Jennifer K Doersam

4

1 reference

14 December 2017

Mine R Ikizler

5

1 reference

14 December 2017

Edith Sannella

6

1 reference

14 December 2017

Peter E Wright

7

1 reference

14 December 2017

1 May 2005

1 reference

Infection Control and Hospital Epidemiology

14 December 2017

1 reference

14 December 2017

26

1 reference

14 December 2017

5

1 reference

14 December 2017

494-500

1 reference

Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults

14 December 2017

1 reference

Studies in man with a cold-recombinant live influenza B virus vaccine

21 January 2018

1 reference

Cold recombinant influenza B/Texas/1/84 vaccine virus (CRB 87): attenuation, immunogenicity, and efficacy against homotypic challenge

21 January 2018

1 reference

Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults

21 January 2018

1 reference

Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial

21 January 2018

1 reference

Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine

21 January 2018

1 reference

The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children

21 January 2018

1 reference

Comparative trial of large-particle aerosol and nose drop administration of live attenuated influenza vaccines

21 January 2018

1 reference

Current status of live attenuated influenza virus vaccine in the US.

21 January 2018

1 reference

Dose response of influenza A/Washington/897/80 (H3N2) avian-human reassortant virus in adult volunteers

21 January 2018

1 reference

Immunologic correlates of protection induced by vaccination

21 January 2018

1 reference

CD154 regulates primate humoral immunity to influenza.

21 January 2018

1 reference

Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults

21 January 2018

1 reference

Cold-adapted recombinant influenza A virus vaccines in seronegative young children

21 January 2018

1 reference

Use of influenza A virus vaccines in seronegative children: live cold-adapted versus inactivated whole virus

21 January 2018

1 reference

Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children

21 January 2018

1 reference

Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children

21 January 2018

1 reference

Studies with a cold-recombinant A/Victoria/3/75 (H3N2) virus. II. Evaluation in adult volunteers

21 January 2018

1 reference

Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in adult volunteers

21 January 2018

1 reference

Intranasal Influenza Vaccine in a Working Population

21 January 2018

1 reference

Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children

21 January 2018

1 reference

Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A H1N1, H3N2, and B vaccine

21 January 2018

1 reference

Evaluation of live attenuated influenza vaccines in children 6-18 months of age: safety, immunogenicity, and efficacy. National Institute of Allergy and Infectious Diseases, Vaccine and Treatment Evaluation Program and the Wyeth-Ayerst ca Influenza

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/502574

1 reference

14 December 2017

1 reference